12 March 2024 : Original article
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Alexander Wiseman
1ADEF*, Tarek Alhamad 2DE, Rita R. Alloway 3DEF, Beatrice P. Concepcion 4DE, Matthew Cooper 5DE, Richard Formica 6DE, Christina L. Klein 7DE, Vineeta Kumar 8DEF, Nicolae Leca 9DE, Fuad Shihab 10DE, David J. Taber 11DE, Sarah Mulnick12ABCDE, Donald M. Bushnell 12BCDE, Monica Hadi 13ABCDE, Suphamai Bunnapradist 14ADEF
DOI: 10.12659/AOT.943498
Ann Transplant 2024; 29:e943498
Table 2 Quality of published evidence: adverse effects with LCPT.
| Panelist | |||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 |
| Low | Moderate | High | Moderate | High | Low |
| Very low | Low | Low | Very low | Low | Low |
| Low | Moderate | Low | Low | Moderate | Moderate |
| Very low | Low | Low | Low | Low | Low |
| High | Moderate | High | Moderate | Moderate | Low |
| Moderate | Low | Moderate | Low | Low | Moderate |
| Moderate | Low | Moderate | Low | Low | Low |
| Moderate | Low | Low | Low | Very low | Low |
| DGF – delayed graft function; N/A – not applicable; NODAT – new-onset diabetes after transplantation; QOL – quality of life. | |||||